Adamantane derivs. for cyto-protection of cells - protects infected and non-infected lymphocytes and other cells, and can be used in treating e.g. AIDs and ARC

摘要

The use of adamantyl derivs. of formula (I) and their acid addn. salts, for the ctyo-protection of non-infected and virus-infected lymphocytes and other cell types is claimed. In (I) R1 to R5 = H or 1-4C opt. branched alkyl. (I) are known cpds. (DE2219256, DE2856393, US4122193 and DE2232735). USE/ADVANTAGE - (I) is used to treat disease where lymphocytes suffer cytopathic changes (claimed). Diseases causing such damage include HIV and human T cell leukaemia/lymphotropic virus type III. Treatment is for patients with HIV, AIDS, ARC and lymphadenopathy-associated virus (LAV) infections. The dose is 0.01-100 mg/kg, pref. in an oral dosage form which reaches the intestines. (I) may be administered simultaneously with other antiviral agents, e.g. 3'-azido-3'-desoxythymidine. In an example, the rate of incorporation of 3H-dThd in mouse lymphocytes was measured after 5 days treatment with memantine (1-amino-3,5-diemthyladamantane), followed by killing the mice and incubating the lymphocytes in foetal calf serum. 3H-dThd was added to the culture medium. In untreated animals, the rate of incorporation was 1.47, with 1 mg/kg it was 1.98, and with 10 mg/kg it was 4.84, in units of 1000 counts/minute/million cells.